Artikelen door HollandBIO

, , ,

Now online: English information about CBG-ZIN Parallel Procedures Pilot

As previously highlighted in our newsletter, the Dutch Medicines Evaluation Board (CBG-MEB) and the National Health Care Institute (Zorginstituut Nederland: ZIN) joined forces in a pilot to accelerate access to innovative medicines in the Netherlands. To inform your international colleagues and/or international affiliates about this opportunity, the information about the “CBG-ZIN Parallel Procedures pilot” is […]

Khondrion granted Orphan Drug Designation

Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the European Commission has granted Orphan Drug Designation (ODD) to its lead asset, KH176, for the treatment of patients with maternally inherited diabetes and deafness (MIDD). MIDD is a subtype of diabetes often accompanied by hearing loss that is caused […]

HollandBIO welcomes AGILeBiotics as a new member

HollandBIO connects and supports the Dutch biotech industry. We represent over 200 companies in the field of medical, agrifood and industrial biotech. And, HollandBIO is growing steadily. Today, we are proud to welcome AGILeBiotics to the HollandBIO community! AGILeBiotics is a spin-off company of the University of Groningen founded by the CEO Dr. Andreas A. […]

SMS-oncology opens new office in Frankfurt, Germany

SMS-ONCOLOGY, a full-service clinical CRO solely dedicated to oncology, is pleased to announce the opening of a new office and the establishment or subsidiary company: SMS-oncology GmbH. SMS-oncology, Europe’s leading oncology CRO, opened the doors of its new office in Frankfurt, Germany. SMS-oncology GmbH is ideally situated in one of the major oncology biotech hubs […]

Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody

Citryll announced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V., BOM Brabant Ventures, BrightGene, and Curie Capital. The proceeds will be used to progress the pre-clinical and clinical development of Citryll’s tACPA antibodies, inhibitors of neutrophil extracellular traps (NETs) and their formation (NETosis). tACPA interferes with the […]

HollandBIO welcomes iClusion as a new member

HollandBIO connects and supports the Dutch biotech industry. We represent 200 companies in the field of medical, agrifood and industrial biotech. And, HollandBIO is growing steadily. Today, we are proud to announce that iClusion joined the HollandBIO community! Clinical trials don’t just advance science; they also serve as in-the-moment treatment alternatives for patients. iClusion aims […]

HollandBIO welcomes Oncode as a new member

HollandBIO connects and supports the Dutch biotech industry. We represent 200 companies in the field of medical, agrifood and industrial biotech. And, HollandBIO is growing steadily. Today, we are proud to announce that Oncode joined the HollandBIO community! Oncode wants to drive breakthrough innovations in the diagnosis and treatment of cancer. The ultimate goal is […]

,

Kiadis updates status of marketing authorization application for ATIR101

Kiadis, a clinical-stage biopharmaceutical company, today announced that it has received feedback from the European Medicines Agency (EMA) related to themarketing authorization application (MAA) seeking approval of ATIR101 in hematopoietic stem cell transplant (HSCT). As previously announced, Kiadis submitted responses to the second Day 180 list of outstanding issues for ATIR101 to EMA in May […]

Gilead to submit new drug application for filgotinib to FDA

Gilead today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company provided an update about the investigational oral, selective JAK1 inhibitor, filgotinib. The company discussed with the agency the Phase 3 FINCH studies, as well as the ongoing Phase 2 MANTA safety study assessing […]

, ,

Staatssecretaris Blokhuis op stoom

Staatssecretaris Blokhuis wil gezondheidswinst door vaccinaties maximaal verzilveren, zo liet hij de Tweede Kamer afgelopen week in een uitgebreide Kamerbrief weten. De Kamerbrief meldt dat de daling van de vaccinatiegraad tot staan is gebracht. Volgens Blokhuis geen reden om op zijn lauweren te rusten: “dit motiveert mij des te meer om onverminderd in te zetten […]